Suppr超能文献

柚皮苷与替莫唑胺联合使用通过促进细胞凋亡抑制胶质母细胞瘤细胞生长:基于网络药理学、实验及代谢组学的研究

Naringin and temozolomide combination suppressed the growth of glioblastoma cells by promoting cell apoptosis: network pharmacology, assays and metabolomics based study.

作者信息

Bisht Priya, Prasad Surendra Rajit, Choudhary Khushboo, Pandey Ruchi, Aishwarya Dande, Aravind Vulli, Ramalingam Peraman, Velayutham Ravichandiran, Kumar Nitesh

机构信息

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER-Hajipur), Export Promotion Industrial Park (EPIP), Hajipur, Bihar, India.

Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER-Hajipur), Export Promotion Industrial Park (EPIP), Hajipur, Bihar, India.

出版信息

Front Pharmacol. 2024 Jul 30;15:1431085. doi: 10.3389/fphar.2024.1431085. eCollection 2024.

Abstract

Glioblastoma, which affects a large number of patients every year and has an average overall lifespan of around 14.6 months following diagnosis stands out as the most lethal primary invasive brain tumor. Currently, surgery, radiation, and chemotherapy with temozolomide (TMZ) are the three major clinical treatment approaches. However, the ability to treat patients effectively is usually limited by TMZ resistance. Naringin, a bioflavonoid with anti-cancer, antioxidant, metal-chelating, and lipid-lowering effects, has emerged as a promising therapeutic option. To explore the targets and pathways of naringin and TMZ in glioblastoma network pharmacology, cell line-based ELISA, flow cytometry, immunocytochemistry, western blotting, and LC-HRMS based metabolomics study were used. The findings through the network pharmacology suggested that the key targets of naringin in the chemosensitization of glioblastoma would be Poly [ADP-ribose] polymerase 1 (PARP-1), O-6-Methylguanine-DNA Methyltransferase (MGMT), and caspases. The functional enrichment analysis revealed that these targets were significantly enriched in important pathways such as p53 signaling, apoptosis, and DNA sensing. Further, the results of the study in U87-MG and T98-G glioblastoma cells demonstrated that TMZ and naringin together significantly reduced the percentage of viability and inhibited the DNA repair enzymes PARP-1 and MGMT, and PI3K/AKT which led to chemosensitization and, in turn, induced apoptosis, which was indicated by increased p53, caspase-3 expression and decreased Bcl2 expression. Additionally, a metabolomics study in T98-G glioblastoma cells using liquid chromatography high-resolution mass spectrometry (LC-HRMS) revealed downregulation of C8-Carnitine (-2.79), L-Hexanoylcarnitine (-4.46), DL-Carnitine (-2.46), Acetyl-L-carnitine (-3.12), Adenine (-1.3), Choline (-2.07), Propionylcarnitine (-1.69), Creatine (-1.33), Adenosine (-0.84), Spermine (-1.42), and upregulation of Palmitic Acid (+1.03) and Sphingosine (+0.89) in the naringin and TMZ treatment groups. In conclusion, it can be said that naringin in combination with TMZ chemosensitized TMZ antiglioma response and induced apoptosis in tumor cells.

摘要

胶质母细胞瘤每年影响大量患者,诊断后的平均总生存期约为14.6个月,是最致命的原发性侵袭性脑肿瘤。目前,手术、放疗和替莫唑胺(TMZ)化疗是三种主要的临床治疗方法。然而,有效治疗患者的能力通常受到TMZ耐药性的限制。柚皮苷是一种具有抗癌、抗氧化、金属螯合和降脂作用的生物黄酮,已成为一种有前景的治疗选择。为了探索柚皮苷和TMZ在胶质母细胞瘤网络药理学中的靶点和途径,采用了基于细胞系的ELISA、流式细胞术、免疫细胞化学、蛋白质印迹法以及基于液相色谱-高分辨质谱(LC-HRMS)的代谢组学研究。通过网络药理学的研究结果表明,柚皮苷在胶质母细胞瘤化疗增敏中的关键靶点是聚[ADP-核糖]聚合酶1(PARP-1)、O-6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)和半胱天冬酶。功能富集分析显示,这些靶点在p53信号传导、凋亡和DNA传感等重要途径中显著富集。此外,在U87-MG和T98-G胶质母细胞瘤细胞中的研究结果表明,TMZ和柚皮苷共同显著降低了细胞活力百分比,并抑制了DNA修复酶PARP-1和MGMT以及PI3K/AKT,从而导致化疗增敏,进而诱导凋亡,这表现为p53、半胱天冬酶-3表达增加和Bcl2表达降低。此外,使用液相色谱高分辨质谱(LC-HRMS)对T98-G胶质母细胞瘤细胞进行的代谢组学研究显示,在柚皮苷和TMZ治疗组中,C8-肉碱(-2.79)、L-己酰肉碱(-4.46)、DL-肉碱(-2.46)、乙酰-L-肉碱(-3.12)、腺嘌呤(-1.3)、胆碱(-2.07)、丙酰肉碱(-1.69)、肌酸(-1.33)、腺苷(-0.84)、精胺(-1.42)下调,棕榈酸(+1.03)和鞘氨醇(+0.89)上调。总之,可以说柚皮苷与TMZ联合使用可使TMZ的抗胶质瘤反应化疗增敏,并诱导肿瘤细胞凋亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad33/11325085/0473fd69dd0b/fphar-15-1431085-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验